tradingkey.logo

Bio Rad Laboratories Inc

BIO
View Detailed Chart

282.260USD

+2.050+0.73%
Close 09/16, 16:00ETQuotes delayed by 15 min
7.64BMarket Cap
23.93P/E TTM

Bio Rad Laboratories Inc

282.260

+2.050+0.73%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.73%

5 Days

-1.29%

1 Month

-1.19%

6 Months

+10.93%

Year to Date

-14.08%

1 Year

-14.53%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-16

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
24 / 207
Overall Ranking
103 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
327.333
Target Price
+16.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Overvalued
The company’s latest PE is 25.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.14M shares, decreasing 12.78% quarter-over-quarter.
Held by First Eagle Investment
Star Investor First Eagle Investment holds 2.52M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Ticker SymbolBIO
CompanyBio Rad Laboratories Inc
CEOMr. Norman D. Schwartz
Websitehttps://www.bio-rad.com/
KeyAI